trending Market Intelligence /marketintelligence/en/news-insights/trending/oOq5vYqCO1U4cG-vkyNfew2 content esgSubNav
In This List

Eisai cancer drug approved as 1st-line treatment in Japan

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Eisai cancer drug approved as 1st-line treatment in Japan

Eisai Co. Ltd. said Treakisym was approved as a first-line treatment in Japan for patients with low-grade B-cell non-Hodgkin lymphoma and mantle cell lymphoma, or MCL, a cancer of white blood cells.

The drug will be used in combination with rituximab to treat patients. It is already approved as a monotherapy for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma and MCL.

Eisai began marketing Treakisym in late-2010 as part of a licensing agreement with SymBio Pharmaceuticals Ltd.